Heartbeam closed at $0.43 on Nov 4, down 0.91%, 87.6% below its 52-week closing high. Volume of 401.2K shares was 0.22× its 20-day average (below normal).
Split-adjusted performance: -27.0% over one month, -50.2% over six months, -75.6% over one year.
Short interest was 2.5M shares at the Oct 15 settlement (6.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BEATHeartbeam | $0.4262 | −0.91% | −50.2% | — | — | — | $24.0M | |
| DRIODarioHealth | $2.96 | −1.33% | −62.9% | −3.6% | −153.1% | 0.0 | $29.0M | Compare |
| ARAYAccuray Incorporated | $0.1565 | +9.14% | −67.2% | −20.9% | −1.9% | — | $18.7M | Compare |
| PMIPicard Medical | $7.51 | −3.47% | −35.3% | — | −191.6% | — | $17.6M | Compare |
| RVPRetractable Technologies | $0.5657 | +0.66% | −18.4% | −31.1% | 38.5% | — | $16.9M | Compare |
| NEPHNephros | $3.23 | −0.31% | +0.3% | +36.2% | 19.9% | 20.2 | $35.1M | Compare |
| TELATELA Bio | $0.7828 | −2.39% | −20.9% | −4.5% | −58.4% | — | $35.3M | Compare |
| MODDModular Medical | $1.71 | −3.39% | −56.3% | — | — | — | $16.2M | Compare |
| NSPRInspireMD | $0.7793 | +18.45% | −32.8% | −0.4% | −808.8% | — | $36.5M | Compare |
No recent articles focused on Heartbeam. 1 articles mention it in passing.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
